



OMPLY HEALTH SHARE ISSUE KEY INFORMATION DOCUMENT

Helsinki, the 2nd of December 2025

This Key Information Document contains essential information about the issuer, Omply Health Oy, and the securities offered. Reviewing this document is recommended so that, as an investor, you understand the related risks and can make an informed investment decision. This Key Information Document was published on 2 December 2025 and remains valid until the end of the share subscription period.

Further information about the issuer and all matters related to the share issue is available directly from the company's management. Contact details can be found at the end of this document.

INFORMATION ABOUT THE COMPANY

Company name and registered domicile	Omply Health Oy ("Omply" or "the Company") Business ID 3546816-4 The Company's registered domicile is Kajaani
Contact information	Sokasaarentie 93, 87800 Kajaani, Finland Company web: www.omply.com LinkedIn: https://www.linkedin.com/company/omply-health/ Youtube: https://www.youtube.com/@OmplyHealth
Board of Directors and Management	Johannes Nikkanen , Chairman of the Board and Co-Founder of the Company. Entrepreneur, investor, and board professional. Over 15 years of experience as an entrepreneur and leader across multiple industries. Background includes several growth journeys, building operational structures, recruitment, sales, and team leadership.

	<p>Anne Ermose, Member of the Board. Expert in cybersecurity and contract law. IT, AI, and strategic senior advisor, board member, and Assistant General Counsel at Microsoft.</p> <p>Christina Brinch Clark, Member of the Board. Expert in international growth within the health sector. Executive Advisor and program director, specializing in health innovations, strategic partnerships, market access, and women’s health. Based in Copenhagen and New York.</p> <p>Hanna Puhakka, Member of the Board. Strategic business and change leader. Health sector executive with strong experience in SaaS solutions, health technology, and service business. Expertise in P&L responsibility, digital health development, go-to-market strategies, and leading international growth.</p> <p>Tuula Nikkanen, Member of the Board and Co-Founder of the Company. Medical doctor and expert in clinical practice. Licentiate of Medicine, Lead Occupational Health Physician at Terveystalo.</p> <p>Tatu Lintukangas, Chief Executive Officer (CEO) and Co-Founder of the Company. Serial entrepreneur and growth builder. A connector of technology, artificial intelligence, and human potential.</p> <p>The Company has a professional Board, a Global Leadership Team, an experienced CEO, and a world-class team of experts. Representatives are located in Finland, Denmark, China, Pakistan, Canada, and Zambia.</p>
<p>Stage of progress</p>	<p>The Company is in a growth phase. It has completed a home-pilot in Finland and the technology has been validated. The Company aims for significant revenue growth in the coming years by expanding into Central Europe, the USA, the Middle East, and China. The Company is pursuing aggressive growth.</p> <p>According to forecasts, it is realistic for the Company to target approximately EUR 15 million in revenue in 2028. The financial projections involve uncertainties and are based on assumptions regarding market development.</p>
<p>Industry</p>	<p>Health technology, digital health services, and the integration of medical devices into a remote care platform.</p>

IMPLEMENTATION OF THE FUNDING ROUND

New shares offered	In the share issue, the Company offers new shares for subscription (“Offer Shares”). The round is open not only to existing shareholders but also to new investors. Omply is not taking on debt but is distributing ownership to new investors. The funding round is used to finance growth, strengthen the cash position, and bring in strategic partners.
Target group	Existing shareholders (41 in total) and new investors.
Target amount to be raised	1 500 000 - 2 500 000 EUR
Company valuation	The current pre-money valuation of the Company has been set at EUR 11.0 million (EUR 10 999 478,04).
Target schedule	The share issue will be carried out from 11 December 2025 to 31 May 2026. However, the round may be closed earlier by a decision of the Board once it has been fully subscribed. The share issue of the sister company, 73Health Oy, was oversubscribed in record time in spring 2025, and a similar outcome is expected for this share issue.
Total number of shares and valuation per share	The total number of shares in the Company is currently 43,135,208. The valuation per share is therefore EUR 0.255.
Dilution	This involves the issuance of new shares. Consequently, the ownership of the current 41 shareholders will be diluted unless they make additional investments in the Company. The current shareholders include medical doctors, attorneys, public figures, executives, business experts, significant companies, a foreign investor, and a Finnish fund. It is expected that existing shareholders will defend their ownership by making new investments.
New shares offered	In the investment round, a minimum of 12.0% (5,882,353 shares) and a maximum of 18.5% (9,803,921 shares) of the Company’s new shares are offered for subscription. The total number of shares in the Company will range between 49,017,561 and 52,939,129 shares.
Minimum investment	The minimum investment in the round is EUR 15,000.12. The minimum investment corresponds to 58,824 shares. With the minimum investment, an investor will receive approximately 0.10–0.11% ownership in the Company, depending on the total number of new shares subscribed in the funding round..
Use of proceeds	The funds raised through the share issue will be used for Omply’s market launch in Finland, for initiating pilot projects in 1–2 additional countries, for continued development of the technology and application platform, and for expanding the doctor network. The objective is to secure working capital for the next 12 months of growth. Use of proceeds: <ul style="list-style-type: none"> ● Go-to-market launch and pilot projects ● Application and platform development ● Supply chain and device procurement

	<ul style="list-style-type: none"> • Team and operational scale-up, doctor network • Regulation and certifications
Subscription commitment	<p>Organizations and private individuals may subscribe for shares.</p> <p>There are no subscriber-specific restrictions.</p> <p>Subscribers must submit a binding electronic subscription notice and pay the share capital.</p> <p>The Board of Directors approves the subscription notices and subscriptions.</p> <p>New shareholders must electronically sign the shareholders' agreement, which ensures equal treatment of all shareholders, as well as the Business Finland Co-Investment Fund (Innovestor Co-Investment Fund) supplementary information attached to the shareholders' agreement. This fund is one of the Company's owners and carried out an extensive legal due diligence process through the law firm Byro Legal just before the spin-off in which Omply Health was established as a separate company for B2C operations.</p>
Exit strategy	<p>The shareholders aim to pursue an exit within 4–5 years, with the Company's valuation targeted at EUR 1 billion (approximately a 100x return on invested capital). Strategic acquisitions are possible, and a stock exchange listing may also be considered.</p>
Next funding round	<p>The next major funding round will be carried out in spring 2027 at a clearly higher valuation.</p>
Further information and subscriptions	<p>This document provides the key information relevant to your investment decision. If you would like further details, for example about the market analysis, the Company's growth strategy, or practical use cases, please contact the Company's management; contact information is provided at the end of this document.</p>

KEY RISKS SPECIFIC TO THE COMPANY AND ITS INDUSTRY

Description of risks	<p>The following risks have been identified as relevant to the Company and its business operations:</p> <p>Technology and supply chain risk: The Company relies on medical devices manufactured by third-party suppliers. Disruptions in the supply chain or issues affecting device manufacturers may impact service availability.</p> <p>Regulatory risk: Healthcare is a highly regulated sector. Changes in legislation (e.g., EUDAMED MDR, FDA, CFDA, OH, DRAP) or challenges in certification processes may delay market entry.</p> <p>Market adoption: The Company is introducing a new operating model (device-assisted remote examination). There is a risk that consumers or doctors may adopt the new technology more slowly than anticipated.</p> <p>Financing risk: If the Company is unable to raise sufficient funding to execute its growth strategy, its operational capabilities may be negatively affected.</p>
-----------------------------	--

KEY RISKS SPECIFIC TO THE NEW SHARES

Description of risks	<p>The investment involves, among others, the following risks:</p> <p>Liquidity risk: The Company's shares are not publicly traded. Investors may not be able to sell their shares at the desired time.</p> <p>Valuation risk: The growth in value of the investment and the expected return are uncertain and depend on the success of the Company's growth strategy.</p> <p>Dilution: Future funding rounds may dilute the ownership of existing shareholders if they do not participate in those rounds.</p>
-----------------------------	---

DESCRIPTION OF BUSINESS OPERATIONS AND MARKET SITUATION

<p>General description</p>	<p>Omply brings healthcare directly into people’s homes. Omply is a smartphone-based remote doctor service that enables a physician to perform a real clinical examination remotely. The service works anywhere a smartphone works and makes it possible to listen to heart, lung, and bowel sounds; examine ears and skin; and measure blood pressure, pulse, oxygen saturation, temperature, and respiratory function easily and quickly, providing access to care exactly when it is needed. No appointment, no waiting, just professional care.</p> <p>When the doctor is in your pocket, healthcare is no longer a system but an experience that happens exactly when a person needs it. Steve Jobs once said that the greatest innovations are the ones that feel obvious only in hindsight. Omply represents precisely this kind of moment in healthcare.</p>
<p>Solution and technology</p>	<p>The service is built on the technology and expertise of its sister company, 73Health, thoroughly tested, and designed in compliance with healthcare regulations and data security laws. Omply owns all IPR rights to the service.</p> <p>Feedback and results from the home-pilot conducted in Finland, from patients, doctors, and partners, have been excellent.</p> <p>A patent application has been filed for the technology (Patent Pending). The European authority EUIPO has granted Omply a registered trademark for its name, logo, and tagline.</p> <p>The ecosystem has been built to be device-agnostic, including wearable sensors and home-use measuring devices, ensuring that Omply is not dependent on any single device manufacturer.</p> <p>Behind the solution is years of research and development and a strong team of doctors, engineers, nurses, and healthcare specialists.</p>
<p>Market and potential</p>	<p>Omply brings together everyday convenience for consumers, relief for burdened healthcare systems, and the opportunity to build a global consumer brand in a rapidly scalable market. The global telehealth market is growing at over 20% annually.</p> <p>The technology is ready, the home pilot in Finland has been a huge success, and strong results have been demonstrated. The devices are certified. Omply is now opening a directed share issue to accelerate market entry and growth. A detailed ramp-up plan exists to support expansion and is followed in the strategic management of the Company.</p>

Contact information	Further information about the Company and the share issue is provided by Tatu Lintukangas CEO, Omply Health Oy email: tatu.lintukangas@omply.com tel: +358 44 055 7773 Johannes Nikkanen Chairman of the Board, Omply Health Oy email: johannes.nikkanen@omply.com tel: +358 40 5173022
----------------------------	---